Center Laboratories, Inc.

4123

TW0004123005

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06/03/2026			5-day change	1st Jan Change
48.95 ^TWD	+1.98%		+11.76%	+17.67%

03-03	Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-13	WuXi XDC Cayman Inc. proposed to acquire 60% stake in BioDlink International Company Limited from a group of shareholders for HKD 1.9 billion.	CI

Center Laboratories, Inc. authorizes a Buyback Plan.

Published on 04/08/2025

S&P Capital IQ

CENTER LABORATORIES, INC.

+1.98%

The Board of Directors of Center Laboratories, Inc. has authorized a buyback plan on April 9, 2025.

Latest news about Center Laboratories, Inc.

03-03	Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-13	WuXi XDC Cayman Inc. proposed to acquire 60% stake in BioDlink International Company Limited from a group of shareholders for HKD 1.9 billion.	CI
11-11	Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
13/08/25	Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
09/06/25	Tranche Update on Center Laboratories, Inc.'s Equity Buyback Plan announced on April 9, 2025.	CI
08/06/25	Center Laboratories, Inc.'s Equity Buyback announced on April 9, 2025, has expired with 9,909,000 shares, representing 1.38% for TWD 383.08 million.	CI
11/05/25	Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
07/05/25	Medeon Biodesign, Inc. cancelled the transaction announced on February 29, 2024	CI
09/04/25	Center Laboratories, Inc. announces an Equity Buyback for 20,000,000 shares, representing 2.76% for TWD 9,141.18 million.	CI
08/04/25	Center Laboratories, Inc. authorizes a Buyback Plan.	CI
23/03/25	Guangzhou Hybot Technology Co., Ltd. announced that it has received CNY 450 million in funding from CS Capital Co., Ltd., Beijing Taiji Huaqing Peicheng Software Technology Co., Ltd., Hydrogenics Corporation, Guangzhou Shuimu Qingyun Equity Investment Partnership Enterprise (Limited Partnership), Beijing Shunyuan Changxin Consulting Management Partnership Enterprise (Limited Partnership, Hainan Yide Investment Partnership Enterprise (Limited Partnership), Center Laboratories, Inc.	CI
14/03/25	Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
11/03/25	Center Laboratories, Inc. Proposes Dividend for Year Ended December 31, 2024	CI
10/03/25	Center Laboratories, Inc. announced a financing transaction	CI
26/02/25	Mycenax Biotech Inc. cancelled the transaction announced on March 13, 2024	CI

Chart Center Laboratories, Inc.

Duration

Period

4123: Dynamic Chart

Center Laboratories Inc is a Taiwan-based company engaged in the development of pharmaceutical products. The Company's products mainly focus on internal liquids, including syrups, suspensions, liquids and other dosage forms. Pharmacological classifications include respiratory tract therapeutics such as cough suppressants, sputum expectorants, asthma medications, and runny nose relief, while antipyretic and analgesic medications and gastrointestinal medications are also in great demand, and a variety of internal liquids and lozenges for the treatment of central nervous system (CNS) such as epilepsy, dysphoria, dementia, and Parkinson's disease have already been introduced into the market. The Company is a specialized manufacturer of internal liquid.

Employees

Sector

Pharmaceuticals

More about the company